2025-524035-39-00尚未招募1 期
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.
Laboratorios Cinfa S.A.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年12月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Rubén Rubén Estepa Sanz
Scientific
Laboratorios Cinfa S.A.
研究点 (1)
Loading locations...
相似试验
已完成
4 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.2023-507991-32-00Sun Pharmaceutical Industries Limited32
招募中
4 期
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes2025-523879-34-00Swedish Match North Europe AB72
已完成
4 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
招募中
4 期
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.2025-522921-37-00Gebro Pharma GmbH36
招募中
1 期
A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants2025-522534-31-00Polpharma Biologics S.A.132